Vanguard Group’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-69,402
| Closed | -$175K | – | 4153 |
|
|
2020
Q2 | $175K | Buy |
69,402
+29,182
| +73% | +$55.3K | ﹤0.01% | 3938 |
|
|
2020
Q1 | $52K | Hold |
40,220
| – | – | ﹤0.01% | 4000 |
|
|
2019
Q4 | $113K | Sell |
40,220
-66,668
| -62% | -$214K | ﹤0.01% | 3998 |
|
|
2019
Q3 | $568K | Sell |
106,888
-18,851
| -15% | -$126K | ﹤0.01% | 3789 |
|
|
2019
Q2 | $1.21M | Buy |
125,739
+8,653
| +7% | +$159K | ﹤0.01% | 3615 |
|
|
2019
Q1 | $3.14M | Buy |
117,086
+62,132
| +113% | +$1.58M | ﹤0.01% | 3309 |
|
|
2018
Q4 | $1.24M | Sell |
54,954
-57,403
| -51% | -$2.24M | ﹤0.01% | 3499 |
|
|
2018
Q3 | $6.2M | Sell |
112,357
-1,884
| -2% | -$120K | ﹤0.01% | 3151 |
|
|
2018
Q2 | $8.16M | Buy |
114,241
+5,276
| +5% | +$373K | ﹤0.01% | 3009 |
|
|
2018
Q1 | $6.69M | Buy |
108,965
+4,333
| +4% | +$380K | ﹤0.01% | 3023 |
|
|
2017
Q4 | $13.2M | Buy |
104,632
+3,305
| +3% | +$423K | ﹤0.01% | 2696 |
|
|
2017
Q3 | $13.9M | Buy |
101,327
+30,383
| +43% | +$4.06M | ﹤0.01% | 2659 |
|
|
2017
Q2 | $10.1M | Sell |
70,944
-10,995
| -13% | -$1.7M | ﹤0.01% | 2762 |
|
|
2017
Q1 | $15.1M | Buy |
81,939
+11,521
| +16% | +$1.29M | ﹤0.01% | 2569 |
|
|
2016
Q4 | $5.67M | Buy |
70,418
+3,359
| +5% | +$266K | ﹤0.01% | 3014 |
|
|
2016
Q3 | $5.14M | Buy |
67,059
+2,526
| +4% | +$202K | ﹤0.01% | 2990 |
|
|
2016
Q2 | $5.55M | Sell |
64,533
-15,252
| -19% | -$1.4M | ﹤0.01% | 2924 |
|
|
2016
Q1 | $7.39M | Sell |
79,785
-23,349
| -23% | -$2.33M | ﹤0.01% | 2776 |
|
|
2015
Q4 | $20.7M | Buy |
103,134
+404
| +0.4% | +$80.6K | ﹤0.01% | 2292 |
|
|
2015
Q3 | $15.3M | Buy |
102,730
+29,522
| +40% | +$21.7M | ﹤0.01% | 2405 |
|
|
2015
Q2 | $69.5M | Buy |
73,208
+23,010
| +46% | +$18.8M | ﹤0.01% | 1757 |
|
|
2015
Q1 | $36.8M | Buy |
50,198
+14,246
| +40% | +$10.7M | ﹤0.01% | 2057 |
|
|
2014
Q4 | $28.6M | Buy |
35,952
+9,761
| +37% | +$5.25M | ﹤0.01% | 2096 |
|
|
2014
Q3 | $10.4M | Buy |
26,191
+1,774
| +7% | +$475K | ﹤0.01% | 2470 |
|
|
2014
Q2 | $6.59M | Buy |
24,417
+2,949
| +14% | +$633K | ﹤0.01% | 2708 |
|
|
2014
Q1 | $4.68M | Buy |
21,468
+6,977
| +48% | +$1.94M | ﹤0.01% | 2862 |
|
|
2013
Q4 | $3.92M | Buy |
14,491
+7,785
| +116% | +$1.86M | ﹤0.01% | 2921 |
|
|
2013
Q3 | $1.53M | Sell |
6,706
-25
| -0.4% | -$4.37K | ﹤0.01% | 3242 |
|
|
2013
Q2 | $946K | Buy |
+6,731
| New | +$1.07M | ﹤0.01% | 3324 |
|
Vanguard Group's TTPH Position: Q3 2020 in Review
Vanguard Group sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2020, closing a stake of 69,402 shares — an estimated $175K sold.
Vanguard Group first reported a position in TTPH in Q2 2013 and held it in 29 quarters. The position peaked at $69.5M in Q2 2015. 1 fund tracked by Wall St. Rank holds TTPH as of Q3 2020.
- Vanguard Group reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Vanguard Group sold 69,402 Tetraphase Pharmaceuticals, Inc. shares in Q3 2020, an estimated $175K.
- Vanguard Group first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Vanguard Group's Tetraphase Pharmaceuticals, Inc. position peaked at $69.5M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2020.
Based on Vanguard Group's 13F filing for Q3 2020, filed 16 Nov 2020.